Neutralizing antibody responses, breakthrough SARS-CoV-2 infections, and symptoms after booster BNT162b2 COVID-19 vaccinations

In a recent study posted to the medRxiv* preprint server, researchers evaluated neutralizing antibody (nAb) responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant induced by booster vaccination (third dose) with Pfizer-BioNTech’s BNT162b2 messenger ribonucleic acid (mRNA) vaccine. They also assessed the association between serological nAb titers, risk of breakthrough infections, and coronavirus disease 2019 (COVID-19) symptomatology.

Study: Neutralizing antibodies following three doses of BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron predominant wave. Image Credit: Christoph Burgstedt/Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Studies have reported that two doses of COVID-19 vaccines (prime vaccination) have conferred immune protection against SARS-CoV-2 variants of concern (VOC); however, the vaccination-induced serological immunity has been reported to wane with time. The continual emergence of SARS-CoV-2 VOCs such as Omicron with greater immune-evasiveness and transmissibility coupled with the eventual waning of immunity has warranted booster vaccinations.

However, data on the association between vaccine-induced immune responses, infection risks, and associated symptoms during the Omicron wave are limited. The authors of the present study previously analyzed NCGM (national center for global health and medicine) staff members of a tertiary hospital in Tokyo who responded to the fourth survey of a case-control study conducted by NCGM in December 2021.

About the study

In the present study, researchers assessed humoral responses to booster vaccinations against Omicron, the risk of breakthrough infections, and associated symptoms during the period of Omicron predominance, i.e., between January and March 2022 among the fifth survey (follow-up) respondents of the previous NCGM study.

The pre-infection anti-Omicron nucleocapsid (N) protein and spike (S) protein immunoglobulin G (IgG) titers were determined and compared among individuals with breakthrough infections (cases) and those without (controls). In-house BNT162b2 vaccinations were administered between March and June 2021 for prime vaccination and between December 2021 and February 2022 for booster vaccination.

The booster vaccine effectiveness (VE) was compared to the second COVID-19 vaccination. The study outcome was PCR (polymerase chain reaction)- or SARS-CoV-2 antigen-confirmed COVID-19 diagnosis, documented in the NCGM in-house registry. The 50% neutralization titer (NT50) values were determined by quantifying serological reductions of CPE (cytopathic effect) of SARS-CoV-2 strains such as the Wuhan-Hu-1 wild-type (wt) strain, Omicron BA.1 VOC, and Omicron BA.2 VOC in VeroE6-TMPRSS2 cells.

To detect COVID-19-associated symptoms such as high fever, severe fatigue, dyspnea, smell and taste disorders, and sore throat among breakthrough infection cases, self-reported data were obtained using questionnaires.

Results

Out of 1,578 initially selected individuals, 30 individuals who received <2 vaccinations at baseline, 49 individuals were administered non-mRNA-based SARS-CoV-2 vaccines, 21 individuals with prior COVID-19 history, and detectable nAbs against the SARS-CoV-2 nucleocapsid (N) protein were excluded from the analysis. As a result, 1,456 individuals were considered for the final analysis.

The incidence rates of breakthrough SARS-CoV-2 infections during Omicron predominance were lower among booster-vaccinated individuals (within three months following vaccination) than prime-vaccinated individuals (within 11 months following vaccination).

Breakthrough SARS-CoV-2 infections were reported in four percent (n=60) of the final sample population between 1 January and 9 March 2022, of which 55% (33 cases) of infections were caused due to Omicron and 22 cases were detected among boosted individuals. The booster VE against SARS-CoV-2 infections concerning the prime vaccination was 55%.

Among the boosted individuals, there were no significant differences in pre-infection anti-Omicron nAb and anti-Omicron S titers between the two groups. In the case group, nAb titers against Omicron BA.1 and Omicron BA.2 were 3.3-fold and 7.2-fold lower than those against SARS-CoV-2 wt, respectively; those against Omicron BA.2 were 2.2-fold lower than those against Omicron BA.1.

Concerning symptoms experienced during SARS-CoV-2 infections, patients identified from the in-house registry were either asymptomatic (17%, n=10) or had mild symptoms (83%, n=50), and three patients with mild symptoms (six percent) required hospitalization. The proportion of asymptomatic patients was higher among booster-vaccinated individuals (20%) than prime-vaccinated individuals (seven percent).

Among the case group, individuals who developed COVID-19 symptoms had lower pre-infection anti-Omicron BA.1 and BA.2 nAb titers than asymptomatic individuals. In particular, those who experienced common cold-like symptoms had significantly lesser pre-infection nAb titers against Omicron BA.1. High fever was significantly associated with lower NAb titers against Omicron BA.2 and smell or taste loss was associated with lower Omicron BA.1 titers.

Overall, the study findings showed that the booster BNT162b2 vaccinations were effective in reducing SARS-CoV-2 infection risks during Omicron predominance in comparison to prime vaccinations. Greater pre-infection nAb titers may not correlate with lower Omicron infection risks among boosted individuals; however, they may have an inverse association with the number of COVID-19 symptoms.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 15 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Pooja Toshniwal Paharia

Written by

Pooja Toshniwal Paharia

Pooja Toshniwal Paharia is an oral and maxillofacial physician and radiologist based in Pune, India. Her academic background is in Oral Medicine and Radiology. She has extensive experience in research and evidence-based clinical-radiological diagnosis and management of oral lesions and conditions and associated maxillofacial disorders.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Toshniwal Paharia, Pooja Toshniwal Paharia. (2023, May 15). Neutralizing antibody responses, breakthrough SARS-CoV-2 infections, and symptoms after booster BNT162b2 COVID-19 vaccinations. News-Medical. Retrieved on October 05, 2024 from https://www.news-medical.net/news/20220920/Neutralizing-antibody-responses-breakthrough-SARS-CoV-2-infections-and-symptoms-after-booster-BNT162b2-COVID-19-vaccinations.aspx.

  • MLA

    Toshniwal Paharia, Pooja Toshniwal Paharia. "Neutralizing antibody responses, breakthrough SARS-CoV-2 infections, and symptoms after booster BNT162b2 COVID-19 vaccinations". News-Medical. 05 October 2024. <https://www.news-medical.net/news/20220920/Neutralizing-antibody-responses-breakthrough-SARS-CoV-2-infections-and-symptoms-after-booster-BNT162b2-COVID-19-vaccinations.aspx>.

  • Chicago

    Toshniwal Paharia, Pooja Toshniwal Paharia. "Neutralizing antibody responses, breakthrough SARS-CoV-2 infections, and symptoms after booster BNT162b2 COVID-19 vaccinations". News-Medical. https://www.news-medical.net/news/20220920/Neutralizing-antibody-responses-breakthrough-SARS-CoV-2-infections-and-symptoms-after-booster-BNT162b2-COVID-19-vaccinations.aspx. (accessed October 05, 2024).

  • Harvard

    Toshniwal Paharia, Pooja Toshniwal Paharia. 2023. Neutralizing antibody responses, breakthrough SARS-CoV-2 infections, and symptoms after booster BNT162b2 COVID-19 vaccinations. News-Medical, viewed 05 October 2024, https://www.news-medical.net/news/20220920/Neutralizing-antibody-responses-breakthrough-SARS-CoV-2-infections-and-symptoms-after-booster-BNT162b2-COVID-19-vaccinations.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Brief behavioral intervention reduces intrusive memories of trauma in healthcare workers post-COVID-19